ES2241507T1 - Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica. - Google Patents
Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica.Info
- Publication number
- ES2241507T1 ES2241507T1 ES03713610T ES03713610T ES2241507T1 ES 2241507 T1 ES2241507 T1 ES 2241507T1 ES 03713610 T ES03713610 T ES 03713610T ES 03713610 T ES03713610 T ES 03713610T ES 2241507 T1 ES2241507 T1 ES 2241507T1
- Authority
- ES
- Spain
- Prior art keywords
- atorvastatin
- semi
- calcic
- approximately
- characteristic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35718102P | 2002-02-15 | 2002-02-15 | |
US357181P | 2002-02-15 | ||
US42532502P | 2002-11-12 | 2002-11-12 | |
US425325P | 2002-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2241507T1 true ES2241507T1 (es) | 2005-11-01 |
Family
ID=27760457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES03713610T Pending ES2241507T1 (es) | 2002-02-15 | 2003-02-19 | Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1480950A4 (no) |
JP (2) | JP2005519076A (no) |
KR (1) | KR100724515B1 (no) |
CN (1) | CN100406436C (no) |
AU (1) | AU2003217653A1 (no) |
CA (1) | CA2475864A1 (no) |
DE (1) | DE03713610T1 (no) |
ES (1) | ES2241507T1 (no) |
HR (1) | HRP20040768A2 (no) |
IS (1) | IS7402A (no) |
MX (1) | MXPA04007939A (no) |
NO (1) | NO20043842L (no) |
PL (1) | PL372303A1 (no) |
WO (1) | WO2003070702A1 (no) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2003070665A2 (en) | 2002-02-19 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Desolvating solvates of atorvastatin hemi-calcium |
CA2508871C (en) * | 2002-11-28 | 2008-09-09 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
WO2006011041A2 (en) | 2004-07-20 | 2006-02-02 | Warner-Lambert Company Llc | Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1) |
EP1711464A2 (en) * | 2004-07-22 | 2006-10-18 | Teva Pharmaceutical Industries Ltd | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
WO2006106372A1 (en) * | 2005-04-08 | 2006-10-12 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | New crystalline atorvastatin hemicalcium salt polymorph form |
DK1957452T3 (da) | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium |
US8080672B2 (en) | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2008108572A1 (en) * | 2007-03-02 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel crystal forms of pyrrolylheptanoic acid derivatives |
KR20120011249A (ko) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
KR101324862B1 (ko) * | 2011-07-12 | 2013-11-01 | (주)에이에스텍 | 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
MA39033A1 (fr) | 2013-11-15 | 2017-11-30 | Akebia Therapeutics Inc | Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations |
CN105055357A (zh) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
KR101723783B1 (ko) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003959A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
CN1423634A (zh) * | 1999-11-17 | 2003-06-11 | 特瓦制药工业有限公司 | 阿托伐他汀钙的多晶型物 |
MXPA02004078A (es) * | 1999-12-17 | 2002-10-11 | Warner Lambert Res & Dev | Un proceso a escala industrial para producir sal de hemi calcio de trihidrato de atorvastatin cristalino. |
ES2258030T3 (es) * | 1999-12-17 | 2006-08-16 | Pfizer Science And Technology Ireland Limited | Procedimiento para producir atorvastatina calcio cristalina. |
SK6592003A3 (en) * | 2000-11-03 | 2004-01-08 | Teva Pharma | Atorvastatin hemi-calcium form VII |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
MXPA03005879A (es) * | 2000-12-27 | 2003-09-10 | Ciba Sc Holding Ag | Formas cristalinas de atorvastatina. |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
GEP20053546B (en) * | 2001-06-29 | 2005-06-10 | Warner Lambert Co | Crystalline Forms of 'R-(R*,R*)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin) |
IL159626A0 (en) * | 2001-07-30 | 2004-06-01 | Reddys Lab Ltd Dr | Crystalline forms of atorvastatin calcium and processes for the preparation thereof |
UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
WO2004022053A1 (en) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
CA2508871C (en) * | 2002-11-28 | 2008-09-09 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
-
2003
- 2003-02-19 DE DE03713610T patent/DE03713610T1/de active Pending
- 2003-02-19 KR KR1020047012591A patent/KR100724515B1/ko not_active IP Right Cessation
- 2003-02-19 AU AU2003217653A patent/AU2003217653A1/en not_active Abandoned
- 2003-02-19 EP EP03713610A patent/EP1480950A4/en not_active Withdrawn
- 2003-02-19 PL PL03372303A patent/PL372303A1/xx not_active Application Discontinuation
- 2003-02-19 ES ES03713610T patent/ES2241507T1/es active Pending
- 2003-02-19 CA CA002475864A patent/CA2475864A1/en not_active Abandoned
- 2003-02-19 JP JP2003569609A patent/JP2005519076A/ja not_active Withdrawn
- 2003-02-19 MX MXPA04007939A patent/MXPA04007939A/es unknown
- 2003-02-19 CN CNB038082071A patent/CN100406436C/zh not_active Expired - Fee Related
- 2003-02-19 WO PCT/US2003/005384 patent/WO2003070702A1/en active Application Filing
-
2004
- 2004-08-13 IS IS7402A patent/IS7402A/is unknown
- 2004-08-25 HR HR20040768A patent/HRP20040768A2/hr not_active Application Discontinuation
- 2004-09-14 NO NO20043842A patent/NO20043842L/no not_active Application Discontinuation
-
2009
- 2009-06-08 JP JP2009137400A patent/JP2009235083A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2005519076A (ja) | 2005-06-30 |
WO2003070702A1 (en) | 2003-08-28 |
CA2475864A1 (en) | 2003-08-28 |
KR20040081202A (ko) | 2004-09-20 |
PL372303A1 (en) | 2005-07-11 |
NO20043842L (no) | 2004-09-14 |
JP2009235083A (ja) | 2009-10-15 |
HRP20040768A2 (en) | 2005-06-30 |
AU2003217653A1 (en) | 2003-09-09 |
CN100406436C (zh) | 2008-07-30 |
EP1480950A1 (en) | 2004-12-01 |
IS7402A (is) | 2004-08-13 |
MXPA04007939A (es) | 2004-11-26 |
DE03713610T1 (de) | 2005-10-20 |
CN1646490A (zh) | 2005-07-27 |
KR100724515B1 (ko) | 2007-06-04 |
EP1480950A4 (en) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2241507T1 (es) | Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica. | |
ES2608961T3 (es) | Nueva forma cristalina VI de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que la contienen | |
ES2391406T3 (es) | Nueva forma cristalina V de la agomelatina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
ES2718926T3 (es) | Formas polimórficas de 3-(4-amino-1-oxo-1,3-dihidroisoindol-2-il)piperidin-2,6-diona | |
BR112018071585B1 (pt) | Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas | |
ES2382806T3 (es) | Compuesto ácido ciclohexanocarboxílico | |
JP2023116645A (ja) | フリー体のクリサボロールの結晶形ならびにそれらの調製方法および使用 | |
JP2006104184A (ja) | ストロンチウムラネレートのアルファー(α)−結晶形、その製造方法、及びそれを含む医薬組成物 | |
ES2694512T3 (es) | Procedimiento mejorado para la preparación de pomalidomida y su purificación | |
ES2356838T5 (es) | Base cristalina de escitalopram y comprimidos orodispersables que contienen escitalopram | |
JP4180368B2 (ja) | 塩酸ベンラファキシンの結晶形 | |
PT106142B (pt) | Processo para a preparação de brometo de tiotrópio | |
ES2671608T3 (es) | Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona | |
JP2014516341A (ja) | アゴメラチンの新しい結晶形vii、その調製方法及び使用並びにこれを含有する医薬組成物 | |
ES2315141A1 (es) | Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina. | |
ES2308304T3 (es) | Procedimientos de preparacion de la olanzapina. | |
KR20130136546A (ko) | 혼합된 결정성 아고멜라틴 (형태-viii), 및 이의 제조 방법 및 용도 및 이를 함유하는 약학적 조성물 | |
ES2303768B1 (es) | Nueva forma cristalina de moxifloxacino clorhidrato. | |
ES2815924T3 (es) | Forma D1 cristalina altamente estable de la sal de monoetanolamina de eltrombopag | |
CA1116629A (en) | Troponyl-oxamic acid derivatives and process therefor | |
ES2553574T3 (es) | Polimorfos de un principio activo farmacéutico | |
KR860001228B1 (ko) | d-및 l-2-(6-메톡시-2-나프틸)-프로피온산 혼합물의 광학적 분할방법 | |
ES2534318B1 (es) | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck | |
ES2906885T3 (es) | Forma cristalina de compuestos de tetraciclina sustituidos con 9-aminometilo y método de preparación para la misma | |
ES2794568T3 (es) | Forma cristalina de un inhibidor del receptor de andrógenos y procedimiento de preparación del mismo |